Reply to “Evaluation of nanomedicines: stick to the basics”
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (7)
Show source-provided references
1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).10.1038/natrevmats.2016.14 ↗
2. McNeil, S. Correspondence to the editor. Nat. Rev. Mater. http://dx.doi.org/10.1038/natrevmats.2016.73 (2016).10.1038/natrevmats.2016.73 ↗
3. Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232, 255–264 (2016).10.1016/j.jconrel.2016.04.028 ↗
4. [No authors listed.] A billion dollar punt. Nat. Biotechnol. 24, 1453 (2006).10.1038/nbt1206-1453 ↗
5. Carroll, J. Merck writes off RNAi, punts Sirna to Alnylam for $175M. FierceBiotech http://www.fiercebiotech.com/financials/merck-writes-off-rnai-punts-sirna-to-alnylam-for-175m (updated 4 Jul 2016).
6. Brunton, L. L., Chabner, B. & Knollmann, B. C. Goodman & Gilman's the Pharmacological Basis of Therapeutics (McGraw-Hill Medical, 2011).
7. Sykes, E. A. et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl Acad. Sci. USA 113, E1142–E1151 (2016).10.1073/pnas.1521265113 ↗